COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,137 Articles (22,693 medRxiv, 8,444 bioRxiv)

Most recent first Previous |  Page 322: Articles 3211-3220  | Next

The Role of ATP Hydrolysis and Product Release in the Translocation Mechanism of SARS-CoV-2 NSP13
Lawal, M. M., Roy, P., McCullagh, M.
10.1101/2023.09.28.560057 — Posted: 2023-09-29
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
Alugubelli, Y. R., Xiao, J., Khatua, K., Kumar, S., Ma, Y., Ma, X., Vulupala, V. R., Atla, S., Blankenship, L., Coleman, D., Neuman, B. W., Liu, W., Xu, S.
10.1101/2023.09.29.560163 — Posted: 2023-09-29
Network-based integrative multi-omics approach reveals biosignatures specific to COVID-19 disease phases.
Agamah, F. E., Ederveen, T. H. A., Skelton, M., Martin, D. P., Chimusa, E. R., 't Hoen, P. A. C.
10.1101/2023.09.29.560110 — Posted: 2023-09-29
SARS-CoV-2 NSP14 governs mutational instability and assists in making new SARS-CoV-2 variants
Hassan, S. S., Bhattacharya, T., Nawn, D., Jha, I., Basu, P., Redwan, E. M., Lundstrom, K., Barh, D., Andrade, B., Tambuwala, M. M., Aljabali, A. A., Hromic-Jahjefendic, A., Baetas-da-Cruz, W., Uversky, V. N.
10.1101/2023.09.28.559966 — Posted: 2023-09-29
Effects of Six Weeks of Supervised Telerehabilitation on Pulmonary Function, Functional Capacity, and Dyspnoea among individuals with Long COVID
Al Mheiri, A., Girish, S., Amaravadi, S. K.
10.1101/2023.09.27.23296254 — Posted: 2023-09-29
Plasma of COVID-19 patients does not alter electrical resistance of human endothelial blood-brain barrier in vitro.
Pociute, A., Kriauciunaite, K., Kausyle, A., Zablockiene, B., Alcauskas, T., Jelinskaite, A., Rudenaite, A., Jancioriene, L., Rocka, S., Verkhratsky, A., Pivoriunas, A.
10.1101/2023.09.28.559927 — Posted: 2023-09-29
An extended catalytic model to assess changes in risk for multiple reinfections with SARS-CoV-2
Lombard, B., Cohen, C., von Gottberg, A., Dushoff, J., van Schalkwyk, C., Pulliam, J.
10.1101/2023.09.27.23296231 — Posted: 2023-09-28
Efficient inhibition of fusion inhibitor HY3000 peptide to SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants
Wu, L., Zheng, A., Tang, Y., Wang, X., Gao, Y., Lei, W., Wu, G., Wang, Q., Gao, G. F.
10.1101/2023.09.28.559747 — Posted: 2023-09-28
Evidence of antigenic drift in the fusion machinery core of SARS-CoV-2 spike
Tan, T. J. C., Odle, A., Lei, R., Matreyek, K. A., Perlman, S., Wong, L.-Y. R., Wu, N. C.
10.1101/2023.09.27.559757 — Posted: 2023-09-28
Inhibiting Glutamine Metabolism Blocks Coronavirus Replication in Mammalian Cells
Greene, K. S., Choi, A., Chen, M., Yang, N., Li, R., Qiu, Y., Lukey, M. J., Rojas, K. S., Shen, J., Wilson, K. F., Katt, W. P., Whittaker, G. R., Cerione, R. A.
10.1101/2023.09.27.559756 — Posted: 2023-09-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).